CTO b12 Labs | YC S25 | https://xitter.cf/t.co/u3rprn2qhQ Prev PhD @EPFL | @mpiMathSci. Building Crows for Chemists, Automating Synthesis 🐦⬛🚀
San Francisco, CA
Joined April 2016
- Tweets831
- Following781
- Followers880
- Likes35.8K
Pinned Tweet
At b12 Labs (YC S25) our mission is making the molecules AI designs. b12 Foundry is a significant step in that direction, and we’re excited to share that today!
Synthesis is a complex problem of carefully orchestrated planning and execution. We have worked intensely on planning (link to selenium), but the execution is what makes it all real.
We partnered with the HTEL at the University of Zurich to convert a state of the art automation facility into an advanced machine for producing molecules.
At the b12 Foundry, our agents and chemists collaborate day and night to produce valuable molecules, reactions and data with a flexibility and quality that few other places in the world can demonstrate.
Today, more than ever, it’s clear that the future of drug development starts with exquisitely designed molecules. We need to be able to make those complex molecules, and to make them efficiently, starting today.
If you have molecules that are hard to make, need experimental data generated, or are simply excited by robots + chemistry + AI, get in touch.
Read on in the comments 👇
#AI4Science #LabAutomation #Chemistry #DrugDiscovery #DeepTech #BioTech #AI
In a world of super intelligence, the bottleneck rapidly becomes execution. The gap between what we can imagine and what we can make has never been wider, but here's @b12Labs to close it 🔥
At b12 Labs our mission is making the molecules AI designs. b12 Foundry is a significant step in that direction, and we’re excited to share that today!
Synthesis is a complex problem of carefully orchestrated planning and execution. We have worked intensely on planning, but the execution is what makes it all real.
We partnered with the HTEL at the University of Zurich to convert a state of the art automation facility into an advanced machine for producing molecules.
At the b12 Foundry, our agents and chemists collaborate day and night to produce valuable molecules, reactions and data with a flexibility and quality that few other places in the world can demonstrate.
Today, more than ever, it’s clear that the future of drug development starts with exquisitely designed molecules.
We need to be able to make those complex molecules, and to make them efficiently, starting today. If you have molecules that are hard to make, need experimental data generated, or are simply excited by robots + chemistry + AI, get in touch.
Read on in the comments 👇
#AIforScience #LabAutomation #Chemistry #DrugDiscovery #DeepTech #BioTech #AI
Andres M Bran retweeted
At b12 Labs our mission is making the molecules AI designs. b12 Foundry is a significant step in that direction, and we’re excited to share that today!
Synthesis is a complex problem of carefully orchestrated planning and execution. We have worked intensely on planning, but the execution is what makes it all real.
We partnered with the HTEL at the University of Zurich to convert a state of the art automation facility into an advanced machine for producing molecules.
At the b12 Foundry, our agents and chemists collaborate day and night to produce valuable molecules, reactions and data with a flexibility and quality that few other places in the world can demonstrate.
Today, more than ever, it’s clear that the future of drug development starts with exquisitely designed molecules.
We need to be able to make those complex molecules, and to make them efficiently, starting today. If you have molecules that are hard to make, need experimental data generated, or are simply excited by robots + chemistry + AI, get in touch.
Read on in the comments 👇
#AIforScience #LabAutomation #Chemistry #DrugDiscovery #DeepTech #BioTech #AI
Andres M Bran retweeted
Very excited about this one: Today we're launching the b12 Foundry in partnership with the High-Throughput Experimentation Lab at the University of Zurich. AI can now design a molecule in seconds, but making it can still take a chemist several weeks. b12 Foundry closes that gap. b12-labs.com/foundry
Read more on our YC launch: ycombinator.com/launches/VMw…
b12 Foundry: b12-labs.com/foundry
Our work on planning: b12-labs.com/blog/selenium-s…
Love this take. There has for a long time been a lot of virtue in abstract ideas that often didn't have consequence - thinking for thinking's sake.
The question now is, if you could just leapfrog your way through theory, where does that take us?
What's the next thing and how to benefit humanity with that?
As a chemist, making new and more exciting stuff in the lab is always the next step!
It sounds insane, because we're used to a particular way of doing research: of giving and receiving credit, of counting beans, of hiring, recruiting, and promoting. And the machine god came to crush that game. The old game is dead. That reasonably causes incredible amounts of dread for many folks, who understand this as the death of research.
But it's not about Research, but the way we played the game. The old game was built around scarcity, scarce compute, scarce students, scarce hours, scarce people who knew the right technique and method etc. Most of a research career went into managing and playing along these constraints. Those walls just came crushing down. One person with a good question can now do what used to take a lab and five years.
You do not need permission, you do not need a big grant, you do not need a professor or researcher title, or a team of twenty experts , or one thousand gpus to stare straight into the first light of the universe.
How absolutely incredible
Andres M Bran retweeted
The world spends roughly $100 billion a year on experimentation in Life-Science. Yet, 93% of drug programs entering Phase I never reach approval.
Halmos Labs is changing that
See how at halmoslabs.com
Andres M Bran retweeted
Today, we're introducing idler – a frontier data research lab.
We've raised a $9M seed round, led by @0xalpo and @FrankieIsLost from @paradigm, with participation from @ycombinator, @LongJourneyVC, and angels including @marrc, @catheryn_li, @dcposch, @JanineLeger, @LynettCapital, @feross, and @nur_daulet_.
This funding helps us build the evals, benchmarks, and reinforcement learning environments that the world's leading frontier labs use to train and measure their models.
Something's cooking at @b12Labs 🔥
Chemistry not always looks this cool. But photochem often does!
Excited about this realease!
@b12Labs products Selenium, Palladium, Cobalt, are named after elements. Glad to see Google pick up the trend 🙂↕️
Andres M Bran retweeted
Exquisitely engineered molecules and exploring novel chemical spaces are the new frontier in drug discovery. We must leave the boring, easily accessible molecules if we want to even get a chance to cure all diseases and harness the power of AI. Make molecules AI agents want.
Breakthroughs in frontier science rarely come from a sudden stroke of luck. Every major leap in AI drug design is the product of years of method development, rigorous engineering, and learning from what came before.
Witnessing the rapid advances in deep reinforcement learning and frontier AI capabilities led to a deep conviction: we could apply these same computational principles to other complex fields, like the engineering of new medicines.
That thinking led to the formation of Isomorphic Labs in 2021. Now, five years on, we have compelling evidence that our AI can unlock therapeutics to a wide range of disease classes. We are confident this technology will fundamentally impact how new medicines are created, from early discovery all the way through development.
In this article, I share the massive opportunity we have to transform human health with AI, and offer a look at the real, measurable progress we’re already making today.
isomorphiclabs.com/articles/…
Every medicine of the future looks like an "exquisitely engineered molecule". @maxjaderberg puts it greatly here, and we love this thesis!
Chemistry should be dictated by the molecule engineer, and not the other way around.
Breakthroughs in frontier science rarely come from a sudden stroke of luck. Every major leap in AI drug design is the product of years of method development, rigorous engineering, and learning from what came before.
Witnessing the rapid advances in deep reinforcement learning and frontier AI capabilities led to a deep conviction: we could apply these same computational principles to other complex fields, like the engineering of new medicines.
That thinking led to the formation of Isomorphic Labs in 2021. Now, five years on, we have compelling evidence that our AI can unlock therapeutics to a wide range of disease classes. We are confident this technology will fundamentally impact how new medicines are created, from early discovery all the way through development.
In this article, I share the massive opportunity we have to transform human health with AI, and offer a look at the real, measurable progress we’re already making today.
isomorphiclabs.com/articles/…
Andres M Bran retweeted
Breakthroughs in frontier science rarely come from a sudden stroke of luck. Every major leap in AI drug design is the product of years of method development, rigorous engineering, and learning from what came before.
Witnessing the rapid advances in deep reinforcement learning and frontier AI capabilities led to a deep conviction: we could apply these same computational principles to other complex fields, like the engineering of new medicines.
That thinking led to the formation of Isomorphic Labs in 2021. Now, five years on, we have compelling evidence that our AI can unlock therapeutics to a wide range of disease classes. We are confident this technology will fundamentally impact how new medicines are created, from early discovery all the way through development.
In this article, I share the massive opportunity we have to transform human health with AI, and offer a look at the real, measurable progress we’re already making today.
isomorphiclabs.com/articles/…
The potential in small molecules is almost understated here - useful and needed for so many things yet honestly we still kinda suck at making them!
Every small molecule is different, not trivial how to even start.
One of those problems where thinking more does help!
If you are wondering how AI will change science and what it makes sense to do right now, there are essentially three things:
1. You can work on solving the problems that are fast and easy to verify. This is a small subset of all problems, but these are the problems that will be most impacted by AI. The Millennium Problems we published are an example.
2. You can work on solving the problems that make other problems hard to verify. For example, one of the slow parts for solving many problems is small molecule synthesis. Make small molecule synthesis fast, and we will solve many more problems. Other things that fall into this category include creating new assays, finding new biomarkers, and accelerating clinical trials.
3. You can go and gather data for the really hard problems (i.e., the ones that are impossible to verify easily). In the age of AI, data is king.
There are many other extremely important and valuable things to be done as well. But they will not benefit from AI nearly to the same extent.
Predictions are nothing without validation in the lab. And to test something, you have to make it first!
Great to see @MSFTResearch's work in @Nature tackling this.
We've evaluated it and it's a strong approach in the single-step class o f models!
Custom-made molecules are advancing medicine, materials, and agriculture, but producing them is slow and expensive. A new Nature paper highlights RetroChimera, a predictive model that helps accelerate chemical synthesis, helping researchers explore a wide range of molecules.: msft.it/6012a5Ogy
Andres M Bran retweeted
Custom-made molecules are advancing medicine, materials, and agriculture, but producing them is slow and expensive. A new Nature paper highlights RetroChimera, a predictive model that helps accelerate chemical synthesis, helping researchers explore a wide range of molecules.: msft.it/6012a5Ogy
Andres M Bran retweeted
We raised a $40M Series A to build the automated lab for agentic biology.
Last week, we shared the work we did with @Anthropic: Claude designed proteins, sent them to our automated wet lab, and got real experimental data back.
We believe this is where biology is going: AI agents designing experiments, running them in automated wet labs, learning from the results and iterating.
But AI can only move as fast as the experiments behind it. To use the potential of AI to cure all diseases, we need to build high-throughput wet lab infrastructure: a “biological gigafactory”.
That’s exactly what we’re doing at Adaptyv.
Over the past year we’ve grown our lab throughput by over 5x and onboarded more than 100 customers, ranging from bio AI labs like @chaidiscovery and @boltz_bio to pharmas like @Roche and @novonordisk to dozens and dozens of new startups that use AI to radically speed up drug discovery.
So cool when an idea becomes available and a bunch of groups tackle it almost simultaneously. Open smiles to iupac translation was missing for a while, and within 2 weeks @adrian_mirza_ and @NicholasRuncie independently released tools for it.
Enabler here are coding agents!
